In vivo transgenic mouse models and in vitro mouse hair follicle stem cell cultures. Researchers generated conditional knockout mice lacking Ldha (lactate dehydrogenase A) specifically in hair follicle stem cells, and separately generated conditional knockout mice lacking Mpc1 (mitochondrial pyruvate carrier 1) to force increased lactate production. Hair cycling was tracked longitudinally.

Deletion of Ldha in hair follicle stem cells prevented their activation -- follicles remained stuck in telogen. Conversely, deletion of Mpc1 (which blocks pyruvate from entering mitochondria, forcing lactate production) accelerated HFSC activation and the hair cycle. The researchers also identified small molecules that increase lactate production by stimulating Myc levels or inhibiting MPC activity and showed these could topically induce the hair cycle in mice.

High -- this is excellent foundational science. Published in Nature Cell Biology (one of the top journals in cell biology), this paper uses rigorous genetic tools (conditional knockouts, lineage tracing) to establish a causal link between lactate metabolism and hair follicle stem cell activation. The logic chain is clean: block lactate production and follicles stay dormant; boost lactate production and follicles activate. Two important caveats. First, this was done in mice, which have a synchronized hair cycle fundamentally different from humans. Mouse results in hair biology frequently fail to translate. Second, the principal investigators (Lowry, Christofk) went on to co-found Pelage Pharmaceuticals, so they have a direct financial interest in these findings being translatable. The science itself is rigorous, but it hasn't been independently replicated by groups without a commercial stake.

• Flores A et al. (2017). Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology PMID 28812580

Medicinal chemistry optimization of UK-5099 analogues. Researchers synthesized novel MPC inhibitor analogues, tested their ability to increase cellular lactate production in vitro, and then applied lead compounds topically to telogen-phase C3H mice to assess hair cycle induction.

Analogues with a 3,5-bis(trifluoromethyl)benzyl group at the N1 position showed substantially better activity than the parent compound UK-5099 at increasing cellular lactate production. When applied topically to mice, lead compounds induced the transition from telogen to anagen, visible as hair regrowth in treated areas.

Moderate. This is an important medicinal chemistry paper that bridges the gap between the basic science discovery (Claim 1) and a drugable compound. It was published in the Journal of Medicinal Chemistry, a well-respected peer-reviewed journal, and comes from the same UCLA group (Lowry, Christofk, Jung) that made the original discovery. The fact that topical application worked in mice is a meaningful step -- it means the compounds can penetrate skin and reach follicles at sufficient concentrations to have biological effects. But the C3H mouse model is among the most permissive hair growth models in preclinical research. The mouse hair cycle is synchronized in a way human scalp hair is not, and many compounds that induce anagen in C3H mice fail in humans. This paper does not report on PP405 (JXL-069) specifically -- it reports on the broader class of optimized MPC inhibitors from which PP405 was eventually selected.

• Liu X et al. (2021). Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss. Journal of Medicinal Chemistry PMID 33534563

Ex vivo human facelift skin. Researchers applied single topical applications of PP405 at 0.006% and 0.06% concentrations to excised human skin containing intact hair follicles. Lactate dehydrogenase (LDH) activity and Ki67 (a marker of cell proliferation) were measured in hair follicle stem cells at 24 hours.

Both concentrations of PP405 increased LDH activity in hair follicle stem cells within 24 hours. The increased LDH activity corresponded with a significant increase in Ki67 signal in the hair bulge region, indicating that quiescent hair follicle stem cells had entered a proliferative state. This confirmed the mouse-derived mechanism operates in human hair follicle tissue.

Moderate-High. This is a critical translational data point. The biggest question hanging over Claims 1 and 2 was whether the lactate/LDH mechanism discovered in mice also operates in human hair follicles. This ex vivo data suggests it does -- PP405 increased both LDH activity and Ki67 in the hair bulge of real human skin within 24 hours. Ex vivo human skin is a strong model because the tissue architecture is intact (follicle, dermis, epidermis are all present). It is more relevant than isolated cell cultures and avoids species-translation concerns from mouse models. The limitations: this data was presented at the AAD 2024 annual meeting as a late-breaking oral presentation, not published in a peer-reviewed journal. Conference presentations do not undergo the same level of scrutiny as journal publications. The data came directly from Pelage Pharmaceuticals -- no independent group has replicated this in human tissue. And ex vivo skin, while valuable, still lacks blood supply, immune context, and the hormonal environment of a living scalp. A 24-hour proliferative signal in excised skin does not guarantee sustained hair regrowth in a living person.

• Pelage Pharmaceuticals (2024). Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo (Late-breaking oral presentation, AAD 2024 Annual Meeting). AAD 2024 Annual Meeting, San Diego

Phase 1 clinical trial in patients with androgenetic alopecia. Participants applied 0.05% PP405 topical gel to the scalp daily for 7 days. The primary endpoints were safety, tolerability, and pharmacokinetics. Ki67 immunostaining of scalp biopsies served as a pharmacodynamic biomarker of hair follicle stem cell activation. The trial concluded in January 2024.

PP405 was safe and well-tolerated. The target pharmacokinetic profile was achieved (implying minimal or no systemic absorption). There was a statistically significant increase in Ki67 signal in hair follicle stem cells compared to baseline after just 7 days of treatment, demonstrating proof of mechanism and target engagement in living human patients.

Moderate. This is meaningful data. Demonstrating that a drug hits its molecular target in living patients is a critical milestone in drug development -- many compounds that work in mice and ex vivo tissue fail to show target engagement in humans. The fact that 7 days of 0.05% PP405 produced statistically significant Ki67 increases in scalp biopsies means the drug is reaching follicles and triggering stem cell proliferation. But Ki67 positivity does not equal hair regrowth. Many biological interventions can induce transient proliferation in stem cells without producing clinically meaningful outcomes. Phase 1 trials are designed for safety, not efficacy -- the sample sizes are tiny, there is often no placebo arm (or a minimal one), and the treatment duration is too short to see clinical hair growth. The data was presented at AAD 2024 alongside the ex vivo data (Claim 3) but has not been published in a peer-reviewed journal. The actual numbers (how many patients, exact Ki67 fold-change, confidence intervals) have not been made publicly available in detail.

• Pelage Pharmaceuticals (2024). Phase 1 clinical data presented at AAD 2024 Annual Meeting. AAD 2024 Annual Meeting, San Diego

Phase 2a randomized, double-blind, vehicle-controlled trial (NCT06393452). 78 men and women with androgenetic alopecia (men: Norwood-Hamilton III vertex to V; women: Savin I-2 to I-4) were randomized to PP405 0.05% gel or vehicle placebo applied once daily for 4 weeks, then followed through Week 12. Primary endpoint was safety and pharmacokinetics. Secondary/exploratory endpoints included hair density changes.

The study met its primary safety endpoint: PP405 was well tolerated with no systemic absorption detected in blood plasma. At Week 8 (4 weeks after treatment ended), 31% of men with a higher degree of hair loss treated with PP405 exhibited a greater than 20% increase in hair density, compared to 0% of men in the placebo group. Additionally, PP405 reportedly induced new hair growth from follicles where no hair was previously present, described as terminal (not vellus) hair in previously bald areas.

Moderate. This is the most clinically relevant data point for PP405 to date, and the headline numbers are genuinely interesting: 31% vs. 0% responder rate is a clean separation from placebo in the right direction. The claim of new terminal hair growth from previously bald follicles, if verified, would be remarkable -- existing FDA-approved treatments (minoxidil, finasteride) primarily thicken miniaturized hairs rather than regrow hair from fully dormant follicles. But the details temper enthusiasm considerably: The 31% figure applies to a subgroup -- men with 'a higher degree of hair loss' -- not the entire PP405 treatment arm. The response rate across the full trial population has not been disclosed. Subgroup analyses in small trials are prone to cherry-picking. N=78 across both sexes, split between PP405 and placebo, means roughly 39 per arm at most. The male subgroup with advanced hair loss is smaller still -- possibly 15-20 patients. At that sample size, a few lucky responders can swing the percentage dramatically. Treatment was only 4 weeks. Standard AGA clinical trials run 6-12 months because hair cycling is slow. The follow-up to Week 12 (8 weeks post-treatment) is interesting for durability signal, but the total observation window is extremely short by hair loss trial standards. No mean hair count change (hairs/cm2) has been reported -- only a responder threshold (>20% increase). This makes it impossible to compare directly with minoxidil or finasteride trial results. Statistical significance for the efficacy endpoints has not been disclosed. The primary endpoint was safety, not efficacy. It is possible the efficacy results are exploratory and not powered for statistical significance. All data comes from a company press release. No peer-reviewed publication, no independent data audit, no patient-level data shared.

• Pelage Pharmaceuticals (2025). Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy. BusinessWire / Company Press Release
• Pelage Pharmaceuticals (2024). Safety, Pharmacokinetics and Efficacy of PP405 in Adults With Androgenetic Alopecia (NCT06393452). ClinicalTrials.gov

Ex vivo human hair follicle organ culture. Researchers at the University of Manchester obtained human scalp hair follicles from consenting patients and treated them with UK-5099 (a well-characterized MPC inhibitor and the parent compound of the class PP405 belongs to). They measured proliferation markers, conducted transcriptomic analysis, and used RNAScope to visualize gene expression changes in intact follicle tissue sections.

MPC inhibition with UK-5099 induced metabolic stress-responsive proliferative arrest throughout the human hair follicle epithelium, including within Keratin 15+ hair follicle stem cells. Transcriptomics revealed a gene expression signature showing disrupted FGF, IGF, TGF-beta, and Wnt signaling, mitochondrial dysfunction, and activation of the integrated stress response (ISR) mediated by ATF4. The ISR inhibitor ISRIB attenuated both the gene expression changes and the proliferative block. The authors note that MPC inhibition causes a metabolic stress that activates a conserved cellular defense program.

Moderate-High -- this is important counterpoint evidence. This study, conducted by an independent research group (University of Manchester) with no ties to Pelage Pharmaceuticals, used a related MPC inhibitor and found that blocking the MPC in human hair follicles triggers a stress response that actually arrests proliferation -- the opposite of what you want for hair growth. The apparent contradiction with Pelage's data (which shows proliferation/Ki67 increases) requires careful interpretation. There are several possible explanations: (1) UK-5099 and PP405 may differ in potency, selectivity, or pharmacokinetics enough to produce different biological outcomes. (2) The dose, duration, and delivery method in ex vivo organ culture versus in vivo topical application may matter enormously. (3) There may be a biphasic response where a mild metabolic stress activates stem cells (hormesis) while a strong stress causes arrest. (4) The initial proliferative burst seen in Pelage's data (Ki67 at 7 days or 24 hours) and the stress-mediated arrest seen in the Manchester data may represent different timepoints of the same biological response. Regardless of the explanation, this paper introduces legitimate mechanistic uncertainty. It suggests that MPC inhibition in human follicles is not simply 'more lactate equals more growth' -- the cellular response is more complex, involving stress pathways that could potentially be harmful with chronic use. This is exactly the kind of question that Phase 3 trials with longer treatment durations need to answer.

• Pye D et al. (2024). Activation of the integrated stress response in human hair follicles. PLOS ONE PMID 38900734